Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C

Journal of Gastroenterology and Hepatology
E OgawaKyushu University Liver Disease Study (KULDS) Group

Abstract

The addition of hepatitis C virus (HCV) NS3/4A protease inhibitors to the pegylated interferon (PEG-IFN) α and ribavirin combination regimen (triple therapy) has dramatically improved treatment outcome. Unfortunately, anemia remains a common adverse effect. This study was done to compare the development of severe anemia during simeprevir- or telaprevir-based triple therapy. This retrospective multicenter study consisted of 837 consecutive Japanese HCV genotype 1 patients treated in a real-world clinical setting, 811 of whom were enrolled (simeprevir 281, telaprevir 530). The inosine triphosphate pyrophosphatase (ITPA) genotype at rs1127354 was determined for all studied patients. Logistic regression was done after propensity score matching to assess the risk of development of severe anemia. Propensity score matching of the entire study population yielded 266 matched pairs. Severe anemia (nadir hemoglobin < 9.0 g/dL) was developed during the treatment period by 81 (30.5%) and 144 (54.1%) patients treated with simeprevir and telaprevir, respectively. Treatment with simeprevir was independently associated with a lower risk of severe anemia (odds ratio 0.25, 95% confidence interval 0.16-0.38, P < 0.0001). Moreover, ITPA genotype, a...Continue Reading

References

May 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P SimmondsD S Chen
Aug 24, 1999·American Journal of Epidemiology·M M Joffe, P R Rosenbaum
Jul 15, 2000·Seminars in Liver Disease·A Wasley, M J Alter
Oct 28, 2004·Gastroenterology·Giovanna FattovichFrancesco Donato
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Richard K SterlingUNKNOWN APRICOT Clinical Investigators
Jun 15, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anaïs Vallet-PichardStanislas Pol
Apr 1, 2011·The New England Journal of Medicine·Bruce R BaconUNKNOWN HCV RESPOND-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Nov 23, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Khayriyyah Mohd HanafiahSteven T Wiersma
Apr 2, 2013·Journal of Hepatology·Norihiro FurusyoUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
May 28, 2013·Journal of Hepatology·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Oct 9, 2013·Alimentary Pharmacology & Therapeutics·E OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Nov 12, 2013·Alimentary Pharmacology & Therapeutics·E OgawaUNKNOWN Kyushu University Liver Disease Study Group
Mar 26, 2014·Gastroenterology·Lai Wei, Anna S F Lok

❮ Previous
Next ❯

Citations

Jun 2, 2016·Pharmacogenomics·Antonio D'AvolioGiovanni Di Perri
Oct 30, 2016·Antiviral Research·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.